ISATUXIMAB-IRFC for Plasma cell myeloma in remission: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 5 adverse event reports in the FDA FAERS database where ISATUXIMAB-IRFC was used for Plasma cell myeloma in remission.

Most Reported Side Effects for ISATUXIMAB-IRFC

Side Effect	Reports	%	Deaths	Hosp.
Infusion related reaction	48	7.9%	1	10
Dyspnoea	42	6.9%	3	13
Off label use	35	5.8%	2	6
Neutropenia	30	4.9%	7	17
Anaemia	23	3.8%	2	6
Disease progression	23	3.8%	16	4
Pyrexia	23	3.8%	5	14
Plasma cell myeloma	22	3.6%	6	3
Thrombocytopenia	22	3.6%	2	2
Diarrhoea	21	3.5%	0	10
Pneumonia	20	3.3%	2	10
Weight increased	18	3.0%	0	0
Weight decreased	17	2.8%	1	1
Nausea	16	2.6%	1	5
Hypertension	15	2.5%	0	4